Back to Journals » Drug Design, Development and Therapy » Volume 12

The effectiveness of long-term course of Sterimar Mn nasal spray for treatment of the recurrence rates of acute allergic rhinitis in patients with chronic allergic rhinitis

Authors Grasso M, de Vincentiis M, Agolli G, Cilurzo F, Grasso R

Received 29 June 2017

Accepted for publication 7 February 2018

Published 3 April 2018 Volume 2018:12 Pages 705—709


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng

Video abstract presented by Michele Grasso.

Views: 643

Michele Grasso,1 Marco de Vincentiis,1 Griselda Agolli,1 Francesco Cilurzo,2 Raffaele Grasso2

1ENT Department, Head and Neck Surgery, University “Sapienza”, Rome, Italy; 2ENT Department, Head and Neck Surgery, Lamezia Terme Hospital, Calabria, Italy

Background: The “cost of illness” of the acute allergic rhinitis (AR) episodes in patients with chronic AR is very high in terms of therapy and quality of life. AR represents a worldwide health problem; despite the fact that many standardized treatments have been proposed and used, the recurrence rate of acute rhinitis episodes in springtime is always higher.
Materials and methods: Sixty consecutive patients (13 F and 17 M in group A, 15 F and 15 M in group B; p=0.60) with chronic AR were enrolled in this prospective, controlled clinical trial. Thirty patients were treated daily for the same 5 months of the following year (2013) with isotonic seawater nasal spray enriched with manganese (Sterimar Mn; 4 puffs/day), whereas 30 patients received only the standard care and were used as control group.
Results: A 5 months course treatment with the nasal Sterimar Mn was able to decrease, significantly (p<0.001), the number of episodes of acute AR (6.33 episodes in the group of treated patients versus 9.33 episodes in control group). Also, the 5 months quality of life reduced over time (Visual Analogue Scale 5th month 9.90 in treated group versus Visual Analogue Scale 5th month 8.72 in control group: p<0.001) without the typical adverse effects of the AR standard care therapy.
Conclusion: This study shows the effectiveness of the use of Sterimar Mn for a 5 months therapy in terms of reduction of the number of episodes of acute AR and effectiveness of intrasubject improvement of Visual Analog Scale (quality of life).

Keywords: chronic allergic rhinitis, acute allergic rhinitis, prevention, nasal detersion, Sterimar Mn

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]